1. Home
  2. MIRM vs CVI Comparison

MIRM vs CVI Comparison

Compare MIRM & CVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CVI
  • Stock Information
  • Founded
  • MIRM 2018
  • CVI 1906
  • Country
  • MIRM United States
  • CVI United States
  • Employees
  • MIRM N/A
  • CVI N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CVI Integrated oil Companies
  • Sector
  • MIRM Health Care
  • CVI Energy
  • Exchange
  • MIRM Nasdaq
  • CVI Nasdaq
  • Market Cap
  • MIRM 2.1B
  • CVI 1.9B
  • IPO Year
  • MIRM 2019
  • CVI 2007
  • Fundamental
  • Price
  • MIRM $46.95
  • CVI $21.07
  • Analyst Decision
  • MIRM Strong Buy
  • CVI Sell
  • Analyst Count
  • MIRM 11
  • CVI 5
  • Target Price
  • MIRM $57.00
  • CVI $23.00
  • AVG Volume (30 Days)
  • MIRM 450.2K
  • CVI 1.6M
  • Earning Date
  • MIRM 02-26-2025
  • CVI 02-18-2025
  • Dividend Yield
  • MIRM N/A
  • CVI 7.12%
  • EPS Growth
  • MIRM N/A
  • CVI N/A
  • EPS
  • MIRM N/A
  • CVI 0.69
  • Revenue
  • MIRM $307,028,000.00
  • CVI $7,865,000,000.00
  • Revenue This Year
  • MIRM $82.14
  • CVI N/A
  • Revenue Next Year
  • MIRM $26.18
  • CVI N/A
  • P/E Ratio
  • MIRM N/A
  • CVI $30.70
  • Revenue Growth
  • MIRM 112.14
  • CVI N/A
  • 52 Week Low
  • MIRM $23.14
  • CVI $15.60
  • 52 Week High
  • MIRM $48.89
  • CVI $38.07
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 65.98
  • CVI 66.74
  • Support Level
  • MIRM $40.55
  • CVI $17.99
  • Resistance Level
  • MIRM $47.25
  • CVI $21.67
  • Average True Range (ATR)
  • MIRM 1.49
  • CVI 0.68
  • MACD
  • MIRM 0.56
  • CVI 0.37
  • Stochastic Oscillator
  • MIRM 95.52
  • CVI 83.83

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CVI CVR Energy Inc.

CVR Energy Inc is a holding company that engages in petroleum refining and nitrogen fertilizer manufacturing through its subsidiaries. subsidiaries include several complex full-coking crude oil refineries, along with a crude oil gathering system, pipelines and storage tanks, and marketing and supply. The company's refineries can process blends of a variety of crude oil ranging from heavy sour to light sweet crude oil. Crude oil for CVR's refineries is supplied through its wholly-owned gathering system and pipeline. From its refineries, CVR supplies products through tanker trucks directly to customers located in close geographic proximity and customers at throughput terminals. The company's customers include retailers, railroads, and farm cooperatives.

Share on Social Networks: